Replied to form 483 of USFDA observations, says Divis Labs

Replied to form 483 of USFDA observations, says Divis Labs

09/01/2017 12:25

Hyderabad-based pharma company Divis Laboratories Ltd on Monday said that it has updated on USFDA inspection of the company’s unit-II at Visakhapatnam.

In a filing to the Bombay Stock Exchange, Divis Laboratories said, “The company has already filed its detailed response to the ‘Form 483’ observations of the USFDA within the time permitted.”

Last month, the US health regulator had made 5 observations after inspection of the company’s manufacturing plant at Visakhapatnam.

Meanwhile, shares of the company were trading at Rs 743.80 apiece, up 0.86 per cent, from previous close on BSE at 12:30 hours.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s